Zoonoses

Anitoa Introduces Rapid, On-site Nucleic Acid Test for New Coronavirus (2019-nCoV)

Retrieved on: 
Tuesday, February 25, 2020
Viruses, Zoonoses, In Saudi Arabia, Middle East respiratory syndrome, Health in Saudi Arabia, Middle East respiratory syndrome-related coronavirus, Coronavirus

MENLO PARK, Calif., Feb. 25, 2020 /PRNewswire/ -- Anitoa Systems, a Silicon Valley biotech company has demonstrated a solution for rapid on-site nucleic acid test of the 2019 novel coronavirus (2019-nCoV).

Key Points: 
  • MENLO PARK, Calif., Feb. 25, 2020 /PRNewswire/ -- Anitoa Systems, a Silicon Valley biotech company has demonstrated a solution for rapid on-site nucleic acid test of the 2019 novel coronavirus (2019-nCoV).
  • Having a R&D center in Hangzhou China, Anitoa tested its solution in hospitals and CDC-labs of China with actual patient samples.
  • "We are encouraged by the very promising performance results of the Maverick solution in detecting the 2019 new coronavirus.
  • The Anitoa Maverick instrument and test kit is provided as a turn-key solution for detecting 2019-nCoV.

Promega Custom Manufacturing Capabilities Aid in Rapid Development of Co-Diagnostics’ New Coronavirus Test

Retrieved on: 
Tuesday, February 25, 2020
Other Health, Other Policy Issues, Pharmaceutical, General Health, Medical devices, Infectious diseases, Hospitals, Public policy, Government, Clinical trials, Science, Biotechnology, Other Science, Health, Research, Medical Supplies, Viruses, Coronaviridae, Animal virology, Zoonoses, Promega, Coronavirus, Severe acute respiratory syndrome-related coronavirus, CoV, Severe acute respiratory syndrome, Emergency Use Authorization

Promega Corporation is being recognized by Utah-based Co-Diagnostics, Inc. for the support Promega custom manufacturing provided in the rapid development and launch of the new Logix Smart COVID-19 Test.

Key Points: 
  • Promega Corporation is being recognized by Utah-based Co-Diagnostics, Inc. for the support Promega custom manufacturing provided in the rapid development and launch of the new Logix Smart COVID-19 Test.
  • Co-Diagnostics yesterday afternoon announced its coronavirus test received CE mark approval and is now available in Europe as an in vitro diagnostic (IVD) .
  • The news comes roughly one month after Co-Diagnostics first began work on a test to detect SARS-CoV-2, the virus that causes COVID-19.
  • In response to the recent coronavirus disease outbreak, Co-Diagnostics used the Promega PCR Optimization Kit to refine their custom master mix for coronavirus testing.

DGAP-News: UET United Electronic Technology AG publishes assessment of 'Sars-CoV-2' (Coronavirus) impact on business development

Retrieved on: 
Tuesday, February 25, 2020
Viruses, Coronaviridae, Animal virology, Zoonoses, Coronavirus, Severe acute respiratory syndrome-related coronavirus, Severe acute respiratory syndrome

UET United Electronic Technology AG (ISIN: DE000A0LBKW6), Eschborn, today publishes an assessment of the business development in connection with the infection "Sars-CoV-2", known as "Coronavirus".

Key Points: 
  • UET United Electronic Technology AG (ISIN: DE000A0LBKW6), Eschborn, today publishes an assessment of the business development in connection with the infection "Sars-CoV-2", known as "Coronavirus".
  • According to the current analysis, it is expected that the increasing spread of the infection and the associated impact on customers will also have an impact on the planned growth of the UET Group.
  • The decision of the UET Group to manufacture all products in Germany was made in 2012.
  • Business includes minimising the impact on the supply chain and doing business with our customers.

Co-Diagnostics, Inc. Receives CE Mark for Novel Coronavirus Test

Retrieved on: 
Monday, February 24, 2020
Science, Research, General Health, Health, Medical devices, Infectious diseases, Hospitals, Genetics, Viruses, Animal diseases, Health in Saudi Arabia, In Saudi Arabia, Middle East respiratory syndrome, Middle East respiratory syndrome-related coronavirus, Zoonoses, IVD, Health

Many other global markets also accept a CE marking as valid regulatory approval following routine local product registration, which allows sales of the Companys IVD into these areas.

Key Points: 
  • Many other global markets also accept a CE marking as valid regulatory approval following routine local product registration, which allows sales of the Companys IVD into these areas.
  • Dwight Egan, Chief Executive Officer of Co-Diagnostics, remarked, Co-Diagnostics has received overwhelming interest in our novel coronavirus diagnostic from all over the world since first announcing its development a month ago.
  • As the disease has spread from China, so have concerns about the global health communitys ability to contain and control it.
  • The rapid development of our COVID-19 test was made possible thanks to our proprietary design process and patented CoPrimer technology platform.

Novel Coronavirus (COVID-19) Study 2020: Preventive Vaccines, Therapeutics and Diagnostics in Development - ResearchAndMarkets.com

Retrieved on: 
Monday, February 24, 2020
Infectious diseases, Pharmaceutical, Health, Viruses, Microbiology, Zoonoses, In Saudi Arabia, Animal virology, Coronaviridae, Middle East respiratory syndrome, Middle East respiratory syndrome-related coronavirus, Coronavirus, Vaccine, Severe acute respiratory syndrome-related coronavirus

The "Novel coronavirus (COVID-19): Preventive Vaccines, Therapeutics and Diagnostics in Development" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Novel coronavirus (COVID-19): Preventive Vaccines, Therapeutics and Diagnostics in Development" report has been added to ResearchAndMarkets.com's offering.
  • Novel coronavirus (COVID-19): Preventive Vaccines, Therapeutics and Diagnostics in Development features an extensive study of the vaccine/drug candidates and diagnostic tests being investigated for COVID-19 infection prevention, treatment and diagnosis.
  • It is worth highlighting that more than 30% of the developers involved in the development of therapeutic agents are academic institutes.
  • New coronavirus (COVID-19) is a previously unidentified strain of coronavirus, that first emerged in the Chinese city of Wuhan in December 2019.

Innovation Pharmaceuticals Submits Material Transfer Agreement to Study Lead Defensin Mimetic Brilacidin for Coronavirus  (COVID-19)

Retrieved on: 
Monday, February 24, 2020
Viruses, Zoonoses, Coronaviridae, Animal virology, Health in Saudi Arabia, In Saudi Arabia, Coronavirus, Severe acute respiratory syndrome-related coronavirus, Middle East respiratory syndrome-related coronavirus, Severe acute respiratory syndrome, Defensin

WAKEFIELD, Mass., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (the Company), a clinical stage biopharmaceutical company, announced today the Companysubmitted a Material Transfer Agreement (MTA) with a leading U.S.-based virology laboratory to research its lead defensin mimetic drug candidate, Brilacidin as a potential novel coronavirus treatment.

Key Points: 
  • WAKEFIELD, Mass., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (the Company), a clinical stage biopharmaceutical company, announced today the Companysubmitted a Material Transfer Agreement (MTA) with a leading U.S.-based virology laboratory to research its lead defensin mimetic drug candidate, Brilacidin as a potential novel coronavirus treatment.
  • Brilacidin has demonstrated broad and robust antibacterial, anti-inflammatory and immunomodulatory properties in multiple FDA clinical trials in different indications.
  • Under terms of the agreement, Brilacidins potential inhibition of SARS-CoV-2, the virus responsible for COVID-19 , is planned to be assessed.
  • Discussions also are underway with a government-funded virology laboratory in Asia, to assess Brilacidin across a range of RNA viruses.

Rapid Dx For Life Calls On All International Airports To Implement Better Screening Of Passengers For Coronavirus

Retrieved on: 
Sunday, February 23, 2020
Viruses, Articles, Veterinary medicine, In Saudi Arabia, Animal virology, Zoonoses, Coronaviridae, Middle East respiratory syndrome, Middle East respiratory syndrome-related coronavirus, Real-time polymerase chain reaction, Coronavirus

Airport tissue-sample screening should be implemented immediately for all inbound international passengers to prevent the spread of the coronavirus into the general population.

Key Points: 
  • Airport tissue-sample screening should be implemented immediately for all inbound international passengers to prevent the spread of the coronavirus into the general population.
  • Rapid Dx LLC is in a position to provide airport authorities the Logix Smart 2019-nCoV CoPrimer qPCR detection kit for the detection of the novel strain of coronavirus for air passengers.
  • We all need to take action now to contain this global outbreak from spreading to every village in every country, potentially infecting hundreds of millions of people.
  • Coronavirus Diagnostic kits are available today for purchase from our Rapid Dx online store.

Meiji Seika Pharma Co., Ltd: Support for Control of Novel Coronavirus in China

Retrieved on: 
Friday, February 21, 2020
Infectious diseases, Fund Raising, Health, Philanthropy, Pharmaceutical, Viruses, Nidovirales, Zoonoses, In Saudi Arabia, Coronaviridae, Animal virology, Coronavirus, Middle East respiratory syndrome-related coronavirus, Meiji Seika, Middle East respiratory syndrome

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan: Meiji) announced today that Meiji decided a financial donation to support coronavirus outbreak control in China.

Key Points: 
  • Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan: Meiji) announced today that Meiji decided a financial donation to support coronavirus outbreak control in China.
  • Daikichiro Kobayashi, President and Representative Director said First of all, we extend our sincerest condolences to the victims and their families.
  • For about 30 years, we have been operating its business in Guangdong and Shandong, and we greatly appreciate the customers and partners all over in China.
  • We sincerely pray for early recovery of Novel coronavirus associated pneumonia patients and the end of virus infection in China.

ImmunoPrecise Launches Coronavirus Vaccine and Therapeutic Antibody Program

Retrieved on: 
Thursday, February 20, 2020
Viruses, Coronaviridae, Animal virology, Zoonoses, Immunology, Severe acute respiratory syndrome-related coronavirus, Coronavirus, Severe acute respiratory syndrome, CoV, Antibody

ImmunoPrecise has designated Dr. Ilse Roodink, the chairwoman of IPA's subsidiary Talem Therapeutic's scientific committee, as the Coronavirus Global Project Leader.

Key Points: 
  • ImmunoPrecise has designated Dr. Ilse Roodink, the chairwoman of IPA's subsidiary Talem Therapeutic's scientific committee, as the Coronavirus Global Project Leader.
  • "We believe that ImmunoPrecise will make an impressive contribution to the global fight against SARS-CoV-2," stated Dr. Jennifer Bath, President and CEO of ImmunoPrecise Antibodies.
  • ImmunoPrecise is an international, full-service, therapeutic antibody discovery company offering species agnostic advancements such as the B cell Select progressive single-cell interrogation technology and the DeepDisplay custom, OmniAb-based phage libraries, as well as the Abthena bispecific program.
  • There is no assurance that the Company will be successful in the development of a vaccine and/or therapeutic against the new coronavirus.

Beroni Group Collaborates with Tianjin University to Develop Novel Solution for Coronavirus (COVID-19)

Retrieved on: 
Thursday, February 20, 2020
Zoonoses, Pneumonia, Severe acute respiratory syndrome, Single-domain antibody, Health, Infection, Medicine, Epidemiology

In order to address this public health crisis, a team of scientists from Tianjin University and from Beroni Group is working to develop a rapid detection method and precision-driven treatment of COVID-19 caused by SARS-CoV-2 infection using nanobody-based technology.

Key Points: 
  • In order to address this public health crisis, a team of scientists from Tianjin University and from Beroni Group is working to develop a rapid detection method and precision-driven treatment of COVID-19 caused by SARS-CoV-2 infection using nanobody-based technology.
  • The development of binding nanobodies will greatly improve the detection rate and accuracy of SARS-CoV-2 and also facilitate the treatment of COVID-19.
  • Jacky Zhang, Chairman and CEO of Beroni Group, said, We are pleased to be working with Tianjin University to develop a novel medical solution for the detection and treatment of COVID-19.
  • Beroni Group has an international network of scientists with the expertise in prevention, detection and control of infectious diseases.